Reata, Calliditas make good on renewed interest in kidney disease with Phase III successes

Two renal diseases are on track for their first approvals after a pair of Phase III studies hit primary endpoints, suggesting renewed interest in the therapeutic area is paying off for patients and investors.

On Monday, Reata Pharmaceuticals Inc. (NASDAQ:RETA) shared data from the Phase III CARDINAL study showing bardoxolone methyl met the primary and key secondary endpoints in chronic kidney disease caused by Alport syndrome. ...